.png)
Sorbonne University
(SU)
Sorbonne University is a world-class research university, presenting the comprehensive disciplinary range of arts, humanities, social sciences, natural sciences, engineering and medicine. The i3 research laboratory is affiliated to Sorbonne University. Directed by David Klatzmann, the general mission of i3 is to perform translational immunology, from bench to bedside. This has been our constant and successful practice over the last 30 years, since i3 started the first European gene therapy trials based. This expertise in translational immunology has been the catalyst of our therapeutic breakthrough with IL-2LD and the focus of our research towards autoimmune and inflammatory diseases. Since then, we maintained our involvement in developing novel cell and gene therapies. Within this context, and having realized the potential (and need) of systems immunology approaches in translational immunology, our specific mission has been to implement translational systems immunology.The i3 specific aims are to (i) advance the frontiers of knowledge in immunology, (ii) develop novel immunotherapies and (iii) identify novel biomarkers of disease phenotypes and progression
Coordinator
David Klatzmann is a translational immunologist developing an interdisciplinary research combining reductionist and systems immunology approaches. Over the last 2 decades, he built up a unique organization that fosters translational immunology, from bench to bedside. This is well exemplified by his discovery of the promising therapeutic potential of low dose IL2 (ld-IL2) in immune-related diseases.
His current research are in the fields of:
Fundamental immunology: I study the development, repertoire and function of T cells, with a special focus on regulatory T cells (Tregs) and systems immunology approaches. I recently contributed to the analyses of T cell receptor repertoires of various T cell subsets. I highlighted the bystander activation of T cells in supposedly specific adaptive immune responses and the role of polyreactive T cells specific for multiple viruses in global immune responses.
Physiopathology: I study the role of Tregs in immune related diseases, and I was one of the senior authors of the first article reporting the role of Tregs in atherosclerosis.
Biotherapy: I develop molecular and cellular Treg-based immunotherapies. I notably pioneered the use of low-dose IL2 as a Treg agonist for the treatment of autoimmune diseases, a strategy already investigated in atherosclerosis. I have led clinical study of IL-2 in more than 20 different autoimmune or inflammatory diseases. I am also designing and developing 3rd generation IL-2 muteins targeted to inflammation sites.